Clinical Trials Browser

Phase 2 × Multiple Myeloma × Cell Count × Clear all

NCT03003728 2020-07-10

2015-10: Expanded Natural Killer Cells and Elotuzumab for High-Risk Myeloma Post- Autologous Stem Cell Transplant (ASCT)

Phase 2 Withdrawn

Multiple Myeloma